Skip to main content
. 2002 Nov;68(11):5585–5594. doi: 10.1128/AEM.68.11.5585-5594.2002

TABLE 2.

Synthetic oligonucleotides used in this study

Oligo- nucleotide Sequencea
RB1 5′-TGCTCGAGCAGCAACGCCTACTTAG-3′
RB2 5′-TGCTCGAGATATTTGTGCGCTATTGAGACTC-3′
RB3 5′-TGCTCGAGTATGAGGCAAATGGATTAGAG-3′
RB4 5′-TGCTCGAGGCGGTCGCTTAGATGT-3′
RB5 5′-GCTGATGGTTATGGTCTAGCGAATG-3′
RB6 5′-TGCGGTGTAGTCATGGCTGTTACT-3′
F1 5′-TGCTCGAGTACGGTTCGATTGGCTATTTGAG-3′
F2 5′-TGCTCGAGCTTTAAGCGGGTAATGTGATTGA-3′
F3 5′-TTGGCGCGCCTGAGCCTAACCAACCCAACCACA-3′
F4 5′-TTGGCGCGCCTGAGGACTGCCAATCATAATGTT-3′
F5 5′-GGCACTGGCGTCGTCTATC-3′
F6 5′-TTTGTTGCGGTATTGAAATTGAAC-3′
F7 5′-TTGGCGCGCCAAGCGTTGGGTGGCATCACTTAG-3′
A2 5′-TGCTCGAGAAGATACCGCCGTTAGTTTC-3′
A4 5′-TTGGCGCGCCAGTGTCGCATTTATTGGCAGA-3′
A7 5′-TGGGCGCGCCATCCAGAATCAGGCAATAGCATT-3′
K1 5′-ATTGCGATCGATTTATGCTTGTAAACCGTT-3′
AK1 5′-TTGGCGCGCCTTATGCTTGTAAACCGTT-3′
a

The underlined regions indicate the following restriction endonuclease sites engineered into the oligonucleotides: XhoI sites in RB1, RB2, RB3, RB4, F1, F2, and A2; AscI sites in F3, F4, F7, A7, and AK1; and a ClaI site in K1.